Table 1.

Baseline patient characteristics

	Historical cohort(n = 213)	Present prospective cohort
		Patients receiving cetuximab (n = 247)	Overall population (n = 301)
Age (years), mean ± SD	62.1 ± 10	61.1 ± 9.1	60.9 ± 9.3
Male	159 (76.6%)	197 (79.8%)	244 (81.1%)
History of allergy	36 (16.9%)	30 (12.1%)	41 (13.6%)
Type of cancer
Head‐and‐neck cancer	100 (46.9 %)	189 (76.5 %)	232 (77.1 %)
Colon cancer	107 (50.2%)	58 (23.5 %)	69 (22.9 %)

Data are presented as n (%) unless otherwise specified. SD, standard deviation